Education
About Us
Working with TipRanks
Follow Us
BioNano Genomics Inc (BNGO)
NASDAQ:BNGO
Total Valuation
BioNano Genomics has a market cap or net worth of $10.80M. The enterprise value is $3.43M.
Market Cap$10.80M
Enterprise Value$3.43M
Share Statistics
BioNano Genomics has 3,364,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,364,000
Owned by Insiders5.72%
Owned by Institutions0.04%
Financial Efficiency
BioNano Genomics’s return on equity (ROE) is -3.17 and return on invested capital (ROIC) is -157.14%.
Return on Equity (ROE)-3.17
Return on Assets (ROA)-1.46
Return on Invested Capital (ROIC)-157.14%
Return on Capital Employed (ROCE)-2.64
Revenue Per Employee314.04K
Profits Per Employee-1.14M
Employee Count98
Asset Turnover0.40
Inventory Turnover2.73
Valuation Ratios
The current PE Ratio of BioNano Genomics is ―. BioNano Genomics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.93
Price to FCF―
Price to Operating Cash Flow-0.20
PEG Ratio―
Income Statement
In the last 12 months, BioNano Genomics had revenue of 30.78M and earned -112.02M in profits. Earnings per share was -3.60K.
Revenue30.78M
Gross Profit380.00K
Operating Income-103.98M
Pretax Income-111.98M
Net Income-112.02M
EBITDA-97.47M
Earnings Per Share (EPS)-3.60K
Cash Flow
In the last 12 months, operating cash flow was -43.55M and capital expenditures -77.00K, giving a free cash flow of -43.63M billion.
Operating Cash Flow-43.55M
Free Cash Flow-43.63M
Free Cash Flow per Share-12.97
Dividends & Yields
BioNano Genomics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.54
52-Week Price Change-90.91%
50-Day Moving Average3.32
200-Day Moving Average7.03
Relative Strength Index (RSI)42.36
Average Volume (3m)94.92K
Important Dates
BioNano Genomics upcoming earnings date is Nov 13, 2025, After Close (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateNov 13, 2025
Ex-Dividend Date―
Financial Position
BioNano Genomics as a current ratio of 1.06, with Debt / Equity ratio of 38.21%
Current Ratio1.06
Quick Ratio0.76
Debt to Market Cap0.72
Net Debt to EBITDA-0.19
Interest Coverage Ratio-359.80
Taxes
In the past 12 months, BioNano Genomics has paid 33.00K in taxes.
Income Tax33.00K
Effective Tax Rate>-0.01
Enterprise Valuation
BioNano Genomics EV to EBITDA ratio is -0.52, with an EV/FCF ratio of -0.74.
EV to Sales1.66
EV to EBITDA-0.52
EV to Free Cash Flow-0.74
EV to Operating Cash Flow-0.74
Balance Sheet
BioNano Genomics has $18.23M in cash and marketable securities with $18.41M in debt, giving a net cash position of $184.00K billion.
Cash & Marketable Securities$18.23M
Total Debt$18.41M
Net Cash$184.00K
Net Cash Per Share$0.05
Tangible Book Value Per Share$13.49
Margins
Gross margin is 3.37%, with operating margin of -337.87%, and net profit margin of -363.98%.
Gross Margin3.37%
Operating Margin-337.87%
Pretax Margin-363.87%
Net Profit Margin-363.98%
EBITDA Margin-316.70%
EBIT Margin-362.93%
Analyst Forecast
The average price target for BioNano Genomics is $5.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.50
Price Target Upside80.92% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-24.04%
EPS Growth Forecast84.11%